Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Inhibition of adipocyte RUNX1/2 enhances adipose tissue thermogenesis through distinct mechanisms

Wang C., He N., Wang S., Lei M., Yao J., Lin L.

Animal Study on Systemic / IV, published in Nat Commun (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Nat Commun (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41927567
PMCID
PMC13216599
DOI
10.1038/s41467-026-71266-6

Abstract (original English)

Thermogenic adipocytes hold significant therapeutic promise for combating obesity and metabolic diseases due to their capacity to dissipate energy as heat. However, the transcriptional regulatory mechanisms underlying thermogenic adipocyte activation remain incompletely understood. Here, we identified RUNX1 and RUNX2 as key transcriptional barriers to thermogenic adipocyte differentiation and activation. RUNX1/2 expression is dynamically suppressed by thermal stress and positively associated with adverse metabolic traits. Genetic deletion of RUNX1 or RUNX2 in adipocytes enhances beige fat formation but differentially influences systemic metabolism in male mice. Conversely, enforced RUNX1/2 expression suppresses thermogenic gene programs and blunts thermogenic adipocyte activation. Mechanistically, RUNX1 recruits HDAC1 to enforce epigenetic silencing of thermogenic loci, whereas RUNX2 governs thermogenic cell fate through phase-separation-dependent repression. Notably, pharmacological inhibition of RUNX1/2 enhances adipose thermogenesis and improves energy metabolism. Our findings unveil an unrecognized role for RUNX in adipose thermogenesis, highlighting their potential as therapeutic targets for metabolic disease intervention.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAdipocytesAnimalsMice, Inbred C57BLMice, KnockoutMiceObesityCell DifferentiationGene Expression RegulationEnergy Metabolism

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research